TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03613311

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
Study: NCT04525495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine treatment
Study: NCT02612987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behaviour Therapy (iCBT)
Study: NCT03840590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CSK AI system
Description: CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
Study: NCT03355638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pranoprofen Eyedrops
Description: Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Supplementation
Description: Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
Study: NCT03509974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseointegrated Steady State Implant
Description: Bone anchored, bone conduction hearing system
Study: NCT04232514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647
Description: Administered HEC74647 200 mg orally once daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647
Description: Administered HEC74647 200 mg orally once daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114
Description: Administered HEC110114 800 mg orally once daily in fed state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC110114
Description: Administered HEC110114 800 mg orally once daily in fed state
Study: NCT02230202

Intervention type: OTHER
Intervention: Flow-mediated dilation
Description: Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.

Intervention type: OTHER
Intervention: Flow-mediated dilation
Description: Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.

Intervention type: OTHER
Intervention: Flow-mediated dilation
Description: Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.

Intervention type: OTHER
Intervention: single blood draw
Description: single blood draw of approximately 45 mL.

Intervention type: OTHER
Intervention: single blood draw
Description: single blood draw of approximately 45 mL.

Intervention type: OTHER
Intervention: single blood draw
Description: single blood draw of approximately 45 mL.
Study: NCT02609217

Intervention type: OTHER
Intervention: Questionnaires and interviews

Intervention type: OTHER
Intervention: Questionnaires and interviews
Study: NCT02194777

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04092621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone in Parenteral Dosage Form
Description: Amiodarone IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Pill
Description: Amiodarone tablet

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Current Cardioversion (DCC)
Description: Convert arrhythmia back to sinus rhythm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate-control therapy
Description: one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
Study: NCT01247870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1 g twice daily for 28-35 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01990885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04193891

Intervention type: OTHER
Intervention: Modified Atkins Diet
Description: The ketogenic diet, where individuals restrict their carbohydrate intake and significantly increase their intake of fats, was initially primarily used in children with severe epilepsy, often due to genetic syndromes. Recently, with the advent of slightly less restrictive forms of ketogenic dietary therapy (e.g. the modified Atkins diet), it has begun to be used in adults with intractable seizures who are not surgical candidates.
Study: NCT03008460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eziclen®/Izinova®
Description: Oral solution taken the evening before the colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean-Prep®
Description: Oral solution taken the evening before the colonoscopy
Study: NCT04081337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT06347757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy
Description: laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy
Description: laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Reflux Alimentary Reconstruction After Laparoscopic Proximal Gastrectomy
Description: laparoscopic proximal gastrectomy with single-tract jejunal interposition (LPG-STJI) versus double-tract reconstruction (LPG-DTR) versus tube-like stomach reconstruction (LPG-TLR).
Study: NCT04431986

Intervention type: OTHER
Intervention: No intervention: secondary use of a database
Description: Statistical analyses
Study: NCT01351792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster® 100/6 µg/unit dose
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbohaler® 200/6 μg/actuation
Description: Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
Study: NCT00691912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal Doxorubicin
Description: 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myocet / Paclitaxel
Description: 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
Study: NCT01516008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Description: Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Description: Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
Study: NCT02483039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AKI Follow-up Clinic
Description: Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
Study: NCT03603210

Intervention type: DEVICE
Intervention: Drug coated balloon angioplasty
Description: Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
Study: NCT01578811

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-MS10
Description: Dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-MS10
Description: Dosage
Study: NCT02130310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CureXcell®
Description: CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline injected at each centimeter of ulcer bed
Study: NCT03508843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive virtual presence
Description: installing the car seat with advice via interactive virtual presence
Study: NCT02154633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Gene Toolkit
Description: Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Family Gene Toolkit
Description: Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
Study: NCT03683797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-discharge call
Description: Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
Study: NCT02054767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: inferior alveolar nerve block injection
Description: -22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: inferior alveolar nerve block injection
Description: -22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: inferior alveolar nerve block injection
Description: -22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
Study: NCT04467554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-chair
Description: Participants will receive 15 sessions of intervention, four weeks in total with a duration of one hour for each session. The focus of the intervention will be trunk rehabilitation.
Study: NCT02036203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCu300A IUB
Description: Spherical copper contraceptive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380A IUD
Description: T-shaped copper IUD
Study: NCT00677352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
Study: NCT00913965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol Tablets 100 mg (Cord Laboratories)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol Tablets 100 mg (Stuart Pharmaceutical)
Study: NCT00677352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
Study: NCT01532128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: 1 mg rasagiline (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: 1 mg rasagiline (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline
Description: 1 mg rasagiline (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 50 mg BIA 9-1067 (single-dose)
Study: NCT04992351

Intervention type: PROCEDURE
Intervention: WALANT
Description: WALANT as anesthesia method for upper and lower limb palstic surgery operations

Intervention type: PROCEDURE
Intervention: WALANT
Description: WALANT as anesthesia method for upper and lower limb palstic surgery operations
Study: NCT00511017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Description: .05 mcg/kg by mouth daily x 28 Days
Study: NCT02892812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Study: NCT03594565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
Study: NCT04465019

Intervention type: DEVICE
Intervention: Exoskeleton Rehabilitation
Description: The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.

Intervention type: DEVICE
Intervention: Exoskeleton Rehabilitation
Description: The EKSO GT® was operated by a Licensed Physical Therapist who was certified to control the device. We followed a strictly established protocol for operating the device during the rehabilitation process as established by the company.
Study: NCT02182973

Intervention type: DIETARY_SUPPLEMENT
Intervention: donor human milk
Description: Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed.
Study: NCT00346021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increasing hat use
Description: Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
Study: NCT00796250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Prednisolone
Description: Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZA
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Infliximab
Description: Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
Study: NCT03948048

Intervention type: DEVICE
Intervention: ECMO
Description: ECMO is used to intervene septic shock and refractory septic shock
Study: NCT03940820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROBO1 CAR-NK cells
Description: The subject will be observed for any side effects during this time and all the adverse events will be recorded.
Study: NCT02753049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer led mHelath behavioral intervention
Description: A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
Study: NCT00885196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study: NCT01394354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
Study: NCT00238433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC\> 1500 for 2 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: 250 mg/m2/day/iv on days -3 and -2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Performed 36-48 hours following last chemotherapy dose.
Study: NCT03116048

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic pain evaluation
Description: Chronic pain assessment with study questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic pain evaluation
Description: Chronic pain assessment with study questionnaire